BCL2 and neoplasm: Given the favorable safety profile of venetoclax, a greater understanding of the mechanisms of primary as well as acquired resistance to this agent is needed to improve or extent venetoclax-based therapies, and potentially other Bcl-2 inhibitors, to various tumor types including solid tumors.